RTP-based G1 Therapeutics files for $115M IPO
G1 Therapeutics Inc., a clinical-stage biopharmaceutical company based in the Research Triangle Park, filed Thursday for an initial public offering of $115 million. G1 Therapeutics focuses on the discovery and development of novel therapeutics for the treatment of cancer. It plans to use proceeds from the offering to advance...
Read More
